Clinical Trials Logo

Recurrent Brain Tumor, Childhood clinical trials

View clinical trials related to Recurrent Brain Tumor, Childhood.

Filter by:
  • None
  • Page 1

NCT ID: NCT04897880 Terminated - Rhabdoid Tumor Clinical Trials

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

NORTH
Start date: January 9, 2019
Phase: Phase 2
Study type: Interventional

This trial is evaluating the anti-tumor activity and side effects of panobinostat in treating patients with osteosarcoma, malignant rhabdoid tumor/atypical teratoid rhabdoid tumor (MRT/ATRT), and neuroblastoma.

NCT ID: NCT03955068 Withdrawn - Ketogenic Diet Clinical Trials

Strict Classic Ketogenic Diet as a Therapy for Recurrent or Progressive and Refractory Brain Tumors in Children

Start date: July 2024
Phase: N/A
Study type: Interventional

This is a pilot study to test the feasibility of implementing a strict classic ketogenic diet among a population of children with recurrent or progressive and refractory brain tumors. Eligible participants will be admitted to the neurosciences floor for 5 days to begin the ketogenic diet either orally, by gastrostomy tube or via nasogastric tube. During the inpatient stay, they will be extensively educated on the diet restrictions and rules. Participants will then continue on the diet at home returning about 17 times over the next 12 months. Daily logs will be kept tracking diet changes, bowel movements and urine ketones. Blood will be collected during the inpatient stay and at all visits for both standard clinical care and research testing.

NCT ID: NCT03299309 Active, not recruiting - Malignant Glioma Clinical Trials

PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma

PRiME
Start date: June 29, 2018
Phase: Phase 1
Study type: Interventional

The primary goal of this prospective clinical trial is to evaluate the safety of PEP-CMV in patients with recurrent medulloblastoma and malignant glioma. Patients with histologically-proven medulloblastoma or malignant glioma who had received prior therapy for their initial diagnosis and subsequently had tumor recurrence/progression may be enrolled any time after recurrence/progression regardless of prior adjuvant therapy. PEP-CMV is a vaccine comprised of Component A, a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. In May 2021, enrollment on the study was temporarily suspended due to delays in vialing the PEP-CMV study vaccine.